Finally, we assessed if ablation of SPATA2 and CYLD can ameliorate immune exclusion in CRC tumors by evaluating tumor growth and intratumoral immune infiltration in BALB/c mice implanted with Spata2-KO, Cyld-KO, or WT CT26 cells. Here, DDX53 is linked to neoplasm.